Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

MLA

Cottron, C., et al. Should We Introduce Early a New Biological Agent in Patients with Inflammatory Bowel Disease after Anti-TNF Discontinuation Due to Severe Anti-TNF-Induced Skin Lesions? A Multicenter Cohort Study. Jan. 2022. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjab232.684⟩.

APA

Cottron, C., Treton, X., Altwegg, R., Reenaers, C., Amiot, A., Fumery, M., Vuitton, L., Peyrin-Biroulet, L., Bouguen, G., Dewit, O., Nancey, S., Caillo, L., Roblin, X., Beylot-Barry, M., Riviere, P., & Laharie, D. (2022). Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study. https://doi.org/10.1093/ecco-jcc/jjab232.684⟩

Chicago

Cottron, C., X. Treton, R. Altwegg, C. Reenaers, A. Amiot, Mathurin Fumery, L. Vuitton, et al. 2022. “Should We Introduce Early a New Biological Agent in Patients with Inflammatory Bowel Disease after Anti-TNF Discontinuation Due to Severe Anti-TNF-Induced Skin Lesions? A Multicenter Cohort Study,” January. doi:10.1093/ecco-jcc/jjab232.684⟩.